PL2542576T3 - Sposoby badań przesiewowych przeciwciał - Google Patents

Sposoby badań przesiewowych przeciwciał

Info

Publication number
PL2542576T3
PL2542576T3 PL11751155.0T PL11751155T PL2542576T3 PL 2542576 T3 PL2542576 T3 PL 2542576T3 PL 11751155 T PL11751155 T PL 11751155T PL 2542576 T3 PL2542576 T3 PL 2542576T3
Authority
PL
Poland
Prior art keywords
methods
screening antibodies
antibodies
screening
Prior art date
Application number
PL11751155.0T
Other languages
English (en)
Inventor
Robert Lyon
Dennis Benjamin
Maureen Ryan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2542576T3 publication Critical patent/PL2542576T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
PL11751155.0T 2010-03-02 2011-02-28 Sposoby badań przesiewowych przeciwciał PL2542576T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30972510P 2010-03-02 2010-03-02
US32343310P 2010-04-13 2010-04-13

Publications (1)

Publication Number Publication Date
PL2542576T3 true PL2542576T3 (pl) 2016-10-31

Family

ID=44542524

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11751155.0T PL2542576T3 (pl) 2010-03-02 2011-02-28 Sposoby badań przesiewowych przeciwciał

Country Status (11)

Country Link
US (2) US9725500B2 (pl)
EP (1) EP2542576B1 (pl)
JP (5) JP5797210B2 (pl)
CN (1) CN102858798B (pl)
CA (1) CA2788289C (pl)
DK (1) DK2542576T3 (pl)
ES (1) ES2581314T3 (pl)
HK (1) HK1180345A1 (pl)
PL (1) PL2542576T3 (pl)
PT (1) PT2542576T (pl)
WO (1) WO2011109308A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107782B2 (en) 2008-01-25 2018-10-23 ProteinSimple Method to perform limited two dimensional separation of proteins and other biologicals
US9725500B2 (en) * 2010-03-02 2017-08-08 Seattle Genetics, Inc. Methods for screening antibodies
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
EP2839276B1 (en) 2012-04-19 2018-06-27 ProteinSimple Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
EP2968582B1 (en) * 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
GB2513405A (en) * 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
US9766206B2 (en) 2013-09-27 2017-09-19 ProteinSimple Apparatus, systems, and methods for capillary electrophoresis
KR102645430B1 (ko) 2013-10-15 2024-03-11 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
CN106536540A (zh) 2014-07-24 2017-03-22 基因泰克公司 将试剂缀合至含有至少一个三硫键的蛋白质中的巯基部分的方法
GB201419185D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resin
KR20180021723A (ko) * 2015-06-29 2018-03-05 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 선택적 제조 방법
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス, インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
WO2003000176A2 (en) 2001-06-20 2003-01-03 Molecular Staging, Inc. Conjugates of reduced antibodies and biomolecules
EE05402B1 (et) * 2001-07-16 2011-04-15 Janssen Pharmaceutica N.V. Meetod bensimidasooli-tüüpi ühendite valmistamiseks ning k?rvalsaadusena moodustunud sulfoonide eemaldamiseks
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20030232386A1 (en) * 2002-06-17 2003-12-18 Shah Dinesh O. Assay conjugate and uses thereof
EP1545613B9 (en) * 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20040038331A1 (en) 2002-08-23 2004-02-26 Reddy M. Parameswara Solid phase synthesis of biomolecule conjugates
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
AU2005218642B2 (en) 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
CN109045307A (zh) * 2004-06-01 2018-12-21 健泰科生物技术公司 抗体-药物偶联物和方法
KR20120064120A (ko) * 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
WO2007002222A2 (en) * 2005-06-20 2007-01-04 Psma Development Company, Llc Psma antibody-drug conjugates
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
MY150643A (en) * 2006-06-22 2014-02-14 Genentech Inc Methods and compositions for targeting hepsin
PL2502938T3 (pl) * 2006-10-27 2015-07-31 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowanie
US20080233660A1 (en) 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
AR072804A1 (es) * 2008-07-15 2010-09-22 Genentech Inc Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales.
CN102472747B (zh) 2009-07-08 2015-04-29 伯乐实验室公司 单克隆抗体的纯化
US9725500B2 (en) * 2010-03-02 2017-08-08 Seattle Genetics, Inc. Methods for screening antibodies

Also Published As

Publication number Publication date
DK2542576T3 (en) 2016-08-01
US9725500B2 (en) 2017-08-08
JP2015227891A (ja) 2015-12-17
CA2788289A1 (en) 2011-09-09
JP5998261B2 (ja) 2016-09-28
WO2011109308A1 (en) 2011-09-09
JP2018076386A (ja) 2018-05-17
CA2788289C (en) 2018-08-21
EP2542576A1 (en) 2013-01-09
US20120322686A1 (en) 2012-12-20
ES2581314T3 (es) 2016-09-05
JP6813928B2 (ja) 2021-01-13
EP2542576A4 (en) 2013-09-04
CN102858798B (zh) 2015-06-17
JP5797210B2 (ja) 2015-10-21
EP2542576B1 (en) 2016-04-20
JP2016216502A (ja) 2016-12-22
CN102858798A (zh) 2013-01-02
US20170298118A1 (en) 2017-10-19
JP2013521498A (ja) 2013-06-10
JP6505882B2 (ja) 2019-04-24
JP6291540B2 (ja) 2018-03-14
JP2019167339A (ja) 2019-10-03
HK1180345A1 (zh) 2013-10-18
PT2542576T (pt) 2016-07-14

Similar Documents

Publication Publication Date Title
HK1180345A1 (zh) 篩選抗體的方法
IL249501A0 (en) A process for creating antibodies
HK1182625A1 (en) Bispecific antibodies
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
IL220404A (en) Antiseptic antibodies
EP2685807A4 (en) SCREENING METHODS
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
HK1194388A1 (zh) 抗缺刻蛋白 抗體
EP2686349A4 (en) METHODS OF ANTIBODY SCREENING
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
IL222533A0 (en) Methods for detecting antibodies
GB201020738D0 (en) Antibodies
EP2558587A4 (en) METHOD FOR DISPLAYING ANTIBODIES
GB201002238D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201120317D0 (en) Screening method
EP2758778A4 (en) SCREENING PROCESS
EP2646824A4 (en) SCREENING METHOD
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
GB201015416D0 (en) Screening method
GB201015419D0 (en) Screening method
GB201006496D0 (en) Screening method